On the other hand, concerning CDKN2A deletion, we found a different situation, since this alteration was found mainly in HGG (426/2114 cases, 53.9%), while in LGG was identified in 8.9% (67/750) of samples, suggesting that this is a late event in progression of gliomas and is involved in tumor malignancy. The gene discussed is CDKN2A; the disease is glioma.